Partnership aims to accelerate the validation and commercialization of non-invasive diagnostic tools for earlier and more accessible detection of Alzheimer's disease
TrilliumBiO, a leader in biomarker discovery and precision diagnostics,announced a strategic collaboration with T-NeuroDx, a pioneering diagnostics company dedicated to developing innovative solutions for detecting neurodegenerative diseases, to advance the development of blood-based biomarker diagnostics for Alzheimer's disease.
This partnership brings together TrilliumBiO's expertise in diagnostic assay development and clinical validation with T-NeuroDx's deep scientific and clinical understanding of Alzheimer's disease pathology and biomarker discovery. Working together, the companies will co-develop and validate blood-based biomarkers that can support earlier diagnosis—addressing one of the most urgent challenges in neurodegenerative care.
"We are proud to partner with T-NeuroDx to bring more accessible, non-invasive diagnostics to patients and providers," said Laura Vivian, CEO of TrilliumBiO. "By combining our diagnostic development capabilities with their cutting-edge biomarker science, we aim to help shift Alzheimer's detection from late-stage confirmation to early, actionable insight."
Blood-based biomarkers represent a transformative opportunity in Alzheimer's disease. As part of the strategic partnership, the teams will commercialize T-Neuro's technology as a Lab Developed Test (LDT) and incorporate it in the evaluation of promising investigational biomarkers that appear earlier in the disease process, designed to support more timely and accessible diagnosis and disease management.
"This partnership accelerates our core mission to advance the early detection of Alzheimer's disease," said Michael Reed, Ph.D., Chief Development Officer of T-NeuroDx. "TrilliumBiO's commitment to providing cutting-edge diagnostic solutions to underserved communities aligns perfectly with our own and strengthens our combined effort to revolutionize early-stage Alzheimer's care."
The initiative will include clinical studies across diverse populations, with the goal of supporting regulatory submissions and the commercialization of clinically validated blood tests for Alzheimer's disease in the coming years.
